Patrick Michael Murphy Sells 7,805 Shares of iRhythm Technologies (NASDAQ:IRTC) Stock

iRhythm Technologies (NASDAQ:IRTC) insider Patrick Michael Murphy sold 7,805 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $135.42, for a total value of $1,056,953.10. Following the transaction, the insider directly owned 60,536 shares in the company, valued at $8,197,785.12. The trade was a 11.42% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Patrick Michael Murphy also recently made the following trade(s):

• On Tuesday, December 2nd, Patrick Michael Murphy sold 2,478 shares of iRhythm Technologies stock. The shares were sold at an average price of $184.83, for a total transaction of $458,008.74.

iRhythm Technologies Stock Up 3.1%

IRTC stock traded up $4.28 during trading on Thursday, hitting $140.18. 390,027 shares of the company’s stock traded hands, compared to its average volume of 725,398. iRhythm Technologies has a 1 year low of $92.52 and a 1 year high of $212.00. The business has a fifty day simple moving average of $162.85 and a two-hundred day simple moving average of $170.94. The firm has a market capitalization of $4.53 billion, a P/E ratio of -100.13 and a beta of 1.06. The company has a quick ratio of 4.48, a current ratio of 4.63 and a debt-to-equity ratio of 4.25.

iRhythm Technologies (NASDAQ:IRTC) last released its quarterly earnings results on Thursday, February 19th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.02 by $0.27. iRhythm Technologies had a negative return on equity of 28.15% and a negative net margin of 5.96%.The firm had revenue of $208.89 million during the quarter, compared to analyst estimates of $202.61 million. During the same period in the previous year, the company posted ($0.04) EPS. The business’s revenue for the quarter was up 27.1% compared to the same quarter last year. Sell-side analysts anticipate that iRhythm Technologies will post -1.98 EPS for the current year.

Institutional Investors Weigh In On iRhythm Technologies

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Root Financial Partners LLC acquired a new stake in shares of iRhythm Technologies during the 3rd quarter worth approximately $30,000. Measured Wealth Private Client Group LLC purchased a new stake in shares of iRhythm Technologies in the 3rd quarter valued at $30,000. GAMMA Investing LLC lifted its position in shares of iRhythm Technologies by 48.4% during the fourth quarter. GAMMA Investing LLC now owns 184 shares of the company’s stock worth $33,000 after purchasing an additional 60 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in iRhythm Technologies by 100.0% in the 3rd quarter. Smartleaf Asset Management LLC now owns 198 shares of the company’s stock valued at $34,000 after buying an additional 99 shares during the period. Finally, FNY Investment Advisers LLC purchased a new position in iRhythm Technologies in the third quarter valued at $34,000.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on IRTC. Freedom Capital upgraded shares of iRhythm Technologies to a “strong-buy” rating in a report on Thursday, January 15th. Canaccord Genuity Group reduced their price objective on iRhythm Technologies from $212.00 to $198.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Needham & Company LLC reiterated a “buy” rating and issued a $244.00 target price on shares of iRhythm Technologies in a research note on Monday, January 12th. Morgan Stanley reiterated an “overweight” rating on shares of iRhythm Technologies in a research report on Monday, January 12th. Finally, Wells Fargo & Company decreased their price objective on shares of iRhythm Technologies from $225.00 to $200.00 and set an “overweight” rating on the stock in a report on Friday, February 20th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $211.62.

Key Stories Impacting iRhythm Technologies

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q4 results beat expectations — revenue grew ~27% year-over-year and EPS beat consensus (reported $0.29 vs. $0.02 est.), which supports the rally and longer-term growth thesis. MarketBeat IRTC summary
• Positive Sentiment: Large institutional positions and recent additions by firms such as Vanguard, RTW and UBS signal continued investor confidence and provide a stable shareholder base. Institutional holdings details
• Neutral Sentiment: Analyst coverage remains mostly positive overall (consensus “Moderate Buy”), but several firms trimmed targets after results while others left or raised targets — a mixed signal that keeps valuation expectations varied. Analyst note roundup
• Negative Sentiment: CEO Quentin Blackford sold 25,540 shares (~$3.46M at ~$135.42), reducing his stake by ~12% — a large, disclosed insider sale that investors often view negatively when concentrated. SEC filing: CEO Form 4
• Negative Sentiment: Other insiders also sold shares this week (EVP Mervin Smith, CAO Marc Rosenbaum, insider Patrick Murphy and Director Abhijit Talwalkar), further reducing internal ownership and adding selling pressure. Relevant filings: Murphy SEC filing Murphy Form 4; Rosenbaum/Smith filings available via MarketBeat links above.
• Negative Sentiment: Short interest jumped ~20% in February to about 3.4M shares (≈10.6% of float), raising the stock’s short-interest ratio to ~5 days — this increases volatility risk and the potential for downside on negative news. Short interest data

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.